Real-time quantitative analysis via Al18F-NOTA-HER2-BCH PET/CT provides a mechanism to monitor HER2 levels during anti-HER2 treatment, thus holding considerable potential for prognostic evaluation, therapeutic decision-making, and detection of treatment resistance in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.